ABCL 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-05

• In January 2026, following an interim review of safety, tolerability, and pharmacodynamic data from healthy volunteers in the Phase 1 portion of the ABCL635 Phase 1/2 clinical trial, we announced the dosing of first patients in the Phase 2 portion of the study.

• In June 2026, we entered into a preclinical research collaboration, option, and license agreement with Jazz Pharmaceuticals PLC (Jazz) to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. Under the agreement, we received a $56.0 million non-refundable upfront payme…

• net sales ranging from mid-single digits to low double-digits. The agreement also provides a mechanism to mutually initiate up to two additional programs, and for us to conduct certain investigational new drug (IND)-enabling studies and manufacture clinical supply for any program under the collabora…

• In July 2026, we entered into a collaboration agreement with Vertex Pharmaceuticals Inc. (Vertex) to research, develop, manufacture, and commercialize multispecific T-cell engagers for autoimmune diseases and other conditions. Under the terms of the agreement, we will lead discovery and early develo…

• •Investing in enhancements to our discovery and development capabilities. Our ability to generate a pipeline of potential first-in-class internal programs and expand our partnerships is dependent on the strength and advantages of our discovery and development capabilities. We intend to maintain our …

相对上期删除的文字 · 来源:10-Q · 2026-05-11

• In January 2026, we announced the dosing of first patients in the Phase 2 portion of the ongoing ABCL635 Phase 1/2 clinical trial, following an interim review of safety, tolerability, and pharmacodynamic data from healthy volunteers from the Phase 1 portion of the study.

• •Investing in enhancements to our discovery and development capabilities. Our ability to generate a pipeline of potential first-in-class internal programs and expand our partnerships is dependent on the strength and advantages of our discovery and development capabilities. We intend to maintain our …

• ABD-147Phase 1 (Fast Track- and orphan drug-designated)Abdera Therapeutics Inc.OncologyPartner-led

• UndisclosedClinical field studyDechra PharmaceuticalsAnimal HealthPartner-led

• NBL-012Phase 1 (pending partner confirmation)NovaRock Biotherapeutics Inc.Dermatology, Gastrointestinal, ImmunologyTrianni license

相对上期新增的文字 · 来源:10-Q · 2026-08-05

• Our “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, are designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the

• Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures are designed to ensure that information required to be disclosed is accumulated and communicated to the issuer’s management, including its …

相对上期删除的文字 · 来源:10-Q · 2026-05-11

• Our “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, are designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, …